BioBuzz

There’s a bottleneck in biopharma most teams don’t see—until it delays everything.

It’s not manufacturing.
It’s not clinical.

It’s testing.

As therapies become more complex—especially in cell and gene therapy—outsourced testing has quietly become one of the biggest constraints on timelines, cost, and scalability.

Our latest piece breaks down the hidden friction:

➡️ Why outsourced testing isn’t scaling with innovation
➡️ How fragmented workflows and long turnaround times stall progress
➡️ What this signals for the future of CDMOs and development strategy

And importantly, where partners like Minaris are stepping in.

With integrated testing, analytical capabilities, and end-to-end support, Minaris is helping shift testing from a bottleneck to a strategic advantage—streamlining workflows, reducing risk, and accelerating timelines across development and commercialization.

But this is bigger than any one company.

👉 This is a system-level signal: infrastructure is racing to catch up with scientific innovation.

📖 Read the full article:
https://news.biobuzz.io/2026/03/31/how-complexity-in-outsourced-testing-creates-a-hidden-bottleneck-in-biopharma-development/

📣 Join the conversation in person

We’re bringing this discussion to the stage at our upcoming BioBuzz event with Minaris—where industry leaders will unpack how testing strategy is evolving and what it means for developers navigating today’s complexity.

👉 RSVP now: https://luma.com/jplvqg9t

Behind Every Therapy: Exploring the Role of Analytics and Biosafety in Bringing Medicines to Market · Luma This event is part of BioBuzz’s Insights to Impact Series, a curated program designed exclusively for life sciences industry leaders and ecosystem builders.…

📢 Calling all life science leaders, entrepreneurs, investors, and regional stakeholders committed to innovation, commercialization, and the growth of the BioHealth Capital Region. 🧬

Join us next Thursday, May 1 in Frederick, MD, for our invite-only event as we discuss 𝗟𝗲𝘃𝗲𝗿𝗮𝗴𝗶𝗻𝗴 𝗔𝗜 𝗔𝗰𝗿𝗼𝘀𝘀 𝘁𝗵𝗲 𝗕𝗶𝗼𝗣𝗵𝗮𝗿𝗺𝗮 𝗩𝗮𝗹𝘂𝗲 𝗖𝗵𝗮𝗶𝗻. 🤖

In addition to presentations from Kemp Proteins, AllSci, and QIAGEN, our powerhouse panel, moderated by Chris Frew, will discuss how AI is transforming every stage of the biopharma lifecycle—accelerating progress and unlocking new possibilities for researchers, companies, and, most importantly, patients.

Hear from:
🐝 Eleanor Howe, CEO, Diamond Age Data Science
🐝 Louis Licamele, Chief Development Officer, EVP of Clinical + Data Science, Bloom Science
🐝 Thom Bethune, Vice President, InfoPathways
🐝 Usama Malik, Investor, President of COEUS + Founder of Regulatory AI startup (stealth)

𝗠𝗲𝘀𝘀𝗮𝗴𝗲 𝘂𝘀 𝗼𝗿 𝗲𝗺𝗮𝗶𝗹 𝗵𝗲𝗹𝗹𝗼[𝗮]𝗯𝗶𝗼𝗯𝘂𝘇𝘇.𝗶𝗼 𝗳𝗼𝗿 𝗺𝗼𝗿𝗲 𝗱𝗲𝘁𝗮𝗶𝗹𝘀.

A 𝗛𝗨𝗚𝗘 thank you to our Impact to Insights 𝗦𝗲𝗿𝗶𝗲𝘀 𝗦𝗽𝗼𝗻𝘀𝗼𝗿𝘀 for making this possible. 👀 We're looking at you Ascend-ABL, CRB, Fulton Bank, Heffron, The Henry M. Jackson Foundation for the Advancement of Military Medicine, InfoPathways Inc., Project Farma, QIAGEN, Maryland Technology Development Corporation - TEDCO, and Workforce Genetics.

And, of course, thank you to our partners like Funktional Brewing Company (cc Jon Rowley, Timothy Olsen, Ph.D., and Josh Ewin) and Wild Bay (cc Sid Sharma) for brewing up some fun.

🚨 𝗜𝗠𝗣𝗢𝗥𝗧𝗔𝗡𝗧 𝗜𝗡𝗙𝗢𝗥𝗠𝗔𝗧𝗜𝗢𝗡 🚨

This invite-only event is FREE for industry leaders and professionals, providing a unique opportunity to gain insights on important industry trends and connect with fellow life science professionals, entrepreneurs, and advocates in a peer-oriented setting. Vendor and service provider attendance is restricted and paid to ensure a high-value program.